A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS
Authors:
- Heidi Krause-SteinraufHKHeidi Krause-Steinrauf
- Barry M MassieBMBarry M Massie
- Prakash DeedwaniaPDPrakash Deedwania
- Dean FollmannDFDean Follmann
- David KovarDKDavid Kovar
- David MurrayDMDavid Murray
- Ron OrenRORon Oren
- Yves RosenbergYRYves Rosenberg
- James YoungJYJames Young
- Michael ZileMZMichael Zile
- Eric EichhornEEEric Eichhorn
- 1 October 2003
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 9 (5) , 354-363
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart FailureCirculation, 2002
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- Racial differences in the frequencies of cardiac ?1-adrenergic receptor polymorphisms: Analysis of c145A>G and c1165G>CHuman Mutation, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The role of third-generation beta-blocking agents in chronic heart failureClinical Cardiology, 1998
- Evaluation of Intrinsic Sympathomimetic Activity of Bucindolol and Carvedilol in Rat HeartPharmacology, 1998
- Rationale, Design, and Organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF)The American Journal of Cardiology, 1997
- Racial Differences in β-Adrenoceptor-Mediated ResponsivenessJournal of Cardiovascular Pharmacology, 1995
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failureJACC, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958